CN102105448B - 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途 - Google Patents
苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途 Download PDFInfo
- Publication number
- CN102105448B CN102105448B CN2009801293473A CN200980129347A CN102105448B CN 102105448 B CN102105448 B CN 102105448B CN 2009801293473 A CN2009801293473 A CN 2009801293473A CN 200980129347 A CN200980129347 A CN 200980129347A CN 102105448 B CN102105448 B CN 102105448B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- mmol
- pyridine
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(CC1)CCC1N(*)C(c1cc(*)cnc1*)=O Chemical compound *C(CC1)CCC1N(*)C(c1cc(*)cnc1*)=O 0.000 description 3
- HJPRDDKCXVCFOH-UHFFFAOYSA-N CCCCN(c1c(C(N2CCCC)=O)[n](CC(C)=O)cn1)C2=O Chemical compound CCCCN(c1c(C(N2CCCC)=O)[n](CC(C)=O)cn1)C2=O HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
- RNVUSZNTVKBCDA-UHFFFAOYSA-N CCOc(cc1[s]c(C(O)=O)cc1c1)c1[O](C)CC Chemical compound CCOc(cc1[s]c(C(O)=O)cc1c1)c1[O](C)CC RNVUSZNTVKBCDA-UHFFFAOYSA-N 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N COc(ccc(C(C1)CNC1=O)c1)c1OC1CCCC1 Chemical compound COc(ccc(C(C1)CNC1=O)c1)c1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- BOLHCUZVJPHIDF-FLSDQSJTSA-N C[C@H]1N[C@@H](C)CN(CCCc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3n[n](C)c(C)c3)=O)=O)c3)ncc3F)c2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(CCCc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3n[n](C)c(C)c3)=O)=O)c3)ncc3F)c2)C1 BOLHCUZVJPHIDF-FLSDQSJTSA-N 0.000 description 1
- OWJJTHVOMMRTCJ-SWBIORQWSA-N C[C@H]1N[C@@H](C)CN(CCc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)c3)ncc3F)c2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(CCc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)c3)ncc3F)c2)C1 OWJJTHVOMMRTCJ-SWBIORQWSA-N 0.000 description 1
- RVXGSDBLDCTNDS-ZNZFJZNRSA-N C[C@H]1N[C@@H](C)CN(Cc(c(O)c2)ccc2-c2cc(Oc(ncc(F)c3)c3C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)ccc2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(Cc(c(O)c2)ccc2-c2cc(Oc(ncc(F)c3)c3C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)ccc2)C1 RVXGSDBLDCTNDS-ZNZFJZNRSA-N 0.000 description 1
- RECANOGJVWFNAY-KEFANGTMSA-N C[C@H]1N[C@@H](C)CN(Cc(cc2)cc(CN3CCOCC3)c2-c2cccc(Oc(ncc(F)c3)c3C(N[C@H](CC3)CC[C@H]3NC(c3c4ncccc4ccc3)=O)=O)c2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(Cc(cc2)cc(CN3CCOCC3)c2-c2cccc(Oc(ncc(F)c3)c3C(N[C@H](CC3)CC[C@H]3NC(c3c4ncccc4ccc3)=O)=O)c2)C1 RECANOGJVWFNAY-KEFANGTMSA-N 0.000 description 1
- AYGAUWOIVRTSOY-JFAUGGILSA-N C[C@H]1N[C@@H](C)CN(Cc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)c3)ncc3F)c2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(Cc(cc2)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3c[s]c(C)n3)=O)=O)c3)ncc3F)c2)C1 AYGAUWOIVRTSOY-JFAUGGILSA-N 0.000 description 1
- WKZCGJACLMLVFO-DZHYTCOUSA-N C[C@H]1N[C@@H](C)CN(Cc(cc2CN3CCOCC3)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3n[n](CCCC4)c4c3)=O)=O)c3)ncc3F)c2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(Cc(cc2CN3CCOCC3)ccc2-c2cccc(Oc(c(C(N[C@H](CC3)CC[C@H]3NC(c3n[n](CCCC4)c4c3)=O)=O)c3)ncc3F)c2)C1 WKZCGJACLMLVFO-DZHYTCOUSA-N 0.000 description 1
- AAHNBOKVOWLFRD-HNRBIFIRSA-N C[n](c(C(F)(F)F)c1)nc1C(N[C@H](CC1)CC[C@H]1NC(c(cc(cn1)F)c1Oc1cccc(-c2ccc(CCN3CCNCC3)cc2)c1)=O)=O Chemical compound C[n](c(C(F)(F)F)c1)nc1C(N[C@H](CC1)CC[C@H]1NC(c(cc(cn1)F)c1Oc1cccc(-c2ccc(CCN3CCNCC3)cc2)c1)=O)=O AAHNBOKVOWLFRD-HNRBIFIRSA-N 0.000 description 1
- JKEMXVKPLUIZHZ-QRRGNZNSSA-N Cc1cccc2nc(C(N[C@H](CC3)CC[C@H]3NC(c(cc(cn3)F)c3Oc3cc(-c4cc(CN5CCNCC5)ccc4)ccc3)=O)=O)c[n]12 Chemical compound Cc1cccc2nc(C(N[C@H](CC3)CC[C@H]3NC(c(cc(cn3)F)c3Oc3cc(-c4cc(CN5CCNCC5)ccc4)ccc3)=O)=O)c[n]12 JKEMXVKPLUIZHZ-QRRGNZNSSA-N 0.000 description 1
- UHPYOGKKAMCDBQ-QRRGNZNSSA-N Cc1cccc2nc(C(N[C@H](CC3)CC[C@H]3NC(c(cc(cn3)F)c3Oc3cc(-c4ccc(CN5CCCC5)cc4)ccc3)=O)=O)c[n]12 Chemical compound Cc1cccc2nc(C(N[C@H](CC3)CC[C@H]3NC(c(cc(cn3)F)c3Oc3cc(-c4ccc(CN5CCCC5)cc4)ccc3)=O)=O)c[n]12 UHPYOGKKAMCDBQ-QRRGNZNSSA-N 0.000 description 1
- SFWCXONFOLYDKS-MEKGRNQZSA-N O=C(c1n[n](cccc2)c2c1)N[C@H](CC1)CC[C@H]1NC(c(cc(cn1)F)c1Oc1cccc(-c2ccc(CCCN3CCNCC3)cc2)c1)=O Chemical compound O=C(c1n[n](cccc2)c2c1)N[C@H](CC1)CC[C@H]1NC(c(cc(cn1)F)c1Oc1cccc(-c2ccc(CCCN3CCNCC3)cc2)c1)=O SFWCXONFOLYDKS-MEKGRNQZSA-N 0.000 description 1
- UEDFRNFASVBNTC-WMPKNSHKSA-N Oc(cc1)cc(CN2CCOCC2)c1-c1cc(Oc(ncc(F)c2)c2C(N[C@H](CC2)CC[C@H]2NC(c(nccc2)c2O)=O)=O)ccc1 Chemical compound Oc(cc1)cc(CN2CCOCC2)c1-c1cc(Oc(ncc(F)c2)c2C(N[C@H](CC2)CC[C@H]2NC(c(nccc2)c2O)=O)=O)ccc1 UEDFRNFASVBNTC-WMPKNSHKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12893908P | 2008-05-27 | 2008-05-27 | |
| US61/128,939 | 2008-05-27 | ||
| PCT/GB2009/050566 WO2009144494A1 (en) | 2008-05-27 | 2009-05-26 | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102105448A CN102105448A (zh) | 2011-06-22 |
| CN102105448B true CN102105448B (zh) | 2013-11-13 |
Family
ID=40821676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801293473A Expired - Fee Related CN102105448B (zh) | 2008-05-27 | 2009-05-26 | 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8273774B2 (https=) |
| EP (2) | EP2297106B1 (https=) |
| JP (1) | JP5607032B2 (https=) |
| KR (1) | KR101605576B1 (https=) |
| CN (1) | CN102105448B (https=) |
| AR (1) | AR071920A1 (https=) |
| AU (1) | AU2009252938B2 (https=) |
| BR (1) | BRPI0912103A2 (https=) |
| CA (1) | CA2721065C (https=) |
| CL (1) | CL2009001298A1 (https=) |
| CY (1) | CY1115566T1 (https=) |
| DK (1) | DK2297106T3 (https=) |
| ES (1) | ES2502527T3 (https=) |
| HK (1) | HK1203482A1 (https=) |
| HR (1) | HRP20140884T1 (https=) |
| MX (1) | MX2010012492A (https=) |
| PE (1) | PE20100144A1 (https=) |
| PL (1) | PL2297106T3 (https=) |
| PT (1) | PT2297106E (https=) |
| RU (1) | RU2509077C2 (https=) |
| SI (1) | SI2297106T1 (https=) |
| TW (1) | TW200951139A (https=) |
| UY (1) | UY31849A (https=) |
| WO (1) | WO2009144494A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
| US9073820B2 (en) | 2011-11-04 | 2015-07-07 | Oregon Health & Science University | Pharmaceutical compositions comprising napthamides |
| US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CN113332292A (zh) * | 2016-02-23 | 2021-09-03 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| FI3851436T3 (fi) | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
| KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220140960A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR102311224B1 (ko) | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
| KR20220146095A (ko) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020639A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Novel compounds |
| US20050020626A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US20050032838A1 (en) * | 2003-07-25 | 2005-02-10 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| CN1652782A (zh) * | 2002-02-11 | 2005-08-10 | 美国辉瑞有限公司 | 用作pde4抑制剂的烟酰胺衍生物 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| DE3770095D1 (de) | 1986-08-21 | 1991-06-20 | Pfizer | Chinazolindione und pyridopyrimidindione. |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2268190A1 (en) | 1997-08-06 | 1999-02-18 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2000045800A2 (en) | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Immunosurpressive effects of pteridine derivatives |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| KR100831534B1 (ko) | 2001-04-30 | 2008-05-22 | 글락소 그룹 리미티드 | 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체 |
| CA2447765C (en) | 2001-05-24 | 2011-01-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| AU2003201745A1 (en) * | 2002-02-11 | 2003-09-04 | Pfizer Limited | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases |
| DE10216339A1 (de) | 2002-04-13 | 2003-10-23 | Boehringer Ingelheim Pharma | Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ES2302938T3 (es) | 2002-10-11 | 2008-08-01 | Pfizer Inc. | Derivados de indol como agonistas beta-2. |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AU2003286024A1 (en) | 2002-11-22 | 2004-06-18 | Daniel Dube | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| US6909002B2 (en) * | 2002-11-22 | 2005-06-21 | Merck & Co., Inc. | Method of preparing inhibitors of phosphodiesterase-4 |
| WO2004105698A2 (en) | 2003-05-29 | 2004-12-09 | Merck & Co., Inc. | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| GB0317509D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317471D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CA2533786A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| EP1651222A1 (en) * | 2003-07-29 | 2006-05-03 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| KR100747401B1 (ko) * | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| US20090246281A1 (en) | 2003-11-03 | 2009-10-01 | Norton Healthcare Ltd. | Soft steroid compositions for use in dry powder inhalers |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US20090093485A1 (en) | 2004-10-29 | 2009-04-09 | Astrazeneca Ab | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
| EP1981885A2 (en) | 2005-10-27 | 2008-10-22 | Merck & Co., Inc. | A method of preparing a 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor |
| WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2009
- 2009-05-26 MX MX2010012492A patent/MX2010012492A/es active IP Right Grant
- 2009-05-26 BR BRPI0912103-0A patent/BRPI0912103A2/pt not_active Application Discontinuation
- 2009-05-26 KR KR1020107026555A patent/KR101605576B1/ko not_active Expired - Fee Related
- 2009-05-26 CN CN2009801293473A patent/CN102105448B/zh not_active Expired - Fee Related
- 2009-05-26 EP EP09754139.5A patent/EP2297106B1/en not_active Not-in-force
- 2009-05-26 TW TW098117462A patent/TW200951139A/zh unknown
- 2009-05-26 EP EP14171857.7A patent/EP2778156B8/en not_active Not-in-force
- 2009-05-26 CA CA2721065A patent/CA2721065C/en not_active Expired - Fee Related
- 2009-05-26 PT PT97541395T patent/PT2297106E/pt unknown
- 2009-05-26 HR HRP20140884AT patent/HRP20140884T1/hr unknown
- 2009-05-26 US US12/471,599 patent/US8273774B2/en not_active Expired - Fee Related
- 2009-05-26 RU RU2010149496/04A patent/RU2509077C2/ru active
- 2009-05-26 DK DK09754139.5T patent/DK2297106T3/da active
- 2009-05-26 AU AU2009252938A patent/AU2009252938B2/en not_active Ceased
- 2009-05-26 WO PCT/GB2009/050566 patent/WO2009144494A1/en not_active Ceased
- 2009-05-26 PL PL09754139T patent/PL2297106T3/pl unknown
- 2009-05-26 SI SI200930997T patent/SI2297106T1/sl unknown
- 2009-05-26 JP JP2011511094A patent/JP5607032B2/ja not_active Expired - Fee Related
- 2009-05-26 ES ES09754139.5T patent/ES2502527T3/es active Active
- 2009-05-27 UY UY0001031849A patent/UY31849A/es unknown
- 2009-05-27 AR ARP090101896A patent/AR071920A1/es unknown
- 2009-05-27 CL CL2009001298A patent/CL2009001298A1/es unknown
- 2009-05-27 PE PE2009000741A patent/PE20100144A1/es not_active Application Discontinuation
-
2011
- 2011-09-07 HK HK15102697.5A patent/HK1203482A1/en unknown
-
2014
- 2014-09-17 CY CY20141100759T patent/CY1115566T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652782A (zh) * | 2002-02-11 | 2005-08-10 | 美国辉瑞有限公司 | 用作pde4抑制剂的烟酰胺衍生物 |
| US20050020639A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Novel compounds |
| US20050020626A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US20050032838A1 (en) * | 2003-07-25 | 2005-02-10 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105448B (zh) | 苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途 | |
| EP2106396B1 (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| CN108698992A (zh) | 用于治疗癌症的2-氰基异吲哚啉衍生物 | |
| EP1999130A1 (en) | Pyridopyrimidine derivatives and their use as pde4 inhibitors | |
| US20080227797A1 (en) | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | |
| CN101111488A (zh) | 新型化合物 | |
| CN101679275B (zh) | 异喹诺酮衍生物及其药学上的应用 | |
| CN101454318A (zh) | 吡啶并嘧啶衍生物及其作为pde4抑制剂的用途 | |
| HK1171754A (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| HK1155167B (en) | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states | |
| HK1120801A (en) | Pyridopyrimidine derivatives as pde4 inhibitors for the treatment of inflammatory and immune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131113 Termination date: 20210526 |